Evidence map›Paper›PMID 35308948›Full record

ArticleAMIA ... Annual Symposium proceedings. AMIA Symposium2021

Controversial Trials First: Identifying Disagreement Between Clinical Guidelines and New Evidence.

Florian Borchert, Laura Meister, Thomas Langer, Markus Follmann, Bert Arnrich, Matthieu-P Schapranow

Abstract read
In one paragraph

Article in AMIA ... Annual Symposium proceedings. AMIA Symposium, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Florian BorchertDigital Health Center, Hasso Plattner Institute, University of Potsdam, Germany.
Laura MeisterDigital Health Center, Hasso Plattner Institute, University of Potsdam, Germany.
Thomas LangerGerman Guideline Program in Oncology, German Cancer Society, Berlin, Germany.
Markus FollmannGerman Guideline Program in Oncology, German Cancer Society, Berlin, Germany.
Bert ArnrichDigital Health Center, Hasso Plattner Institute, University of Potsdam, Germany.
Matthieu-P SchapranowDigital Health Center, Hasso Plattner Institute, University of Potsdam, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clinical guidelines integrate latest evidence to support clinical decision-making. As new research findings are published at an increasing rate, it would be helpful to detect when such results disagree with current guideline recommendations. In this work, we describe a software system for the automatic identification of disagreement between clinical guidelines and published research. A critical feature of the system is the extraction and cross-lingual normalization of information through natural language processing. The initial version focuses on the detection of cancer treatments in clinical trial reports that are not addressed in oncology guidelines. We evaluate the relevance of trials retrieved by our system retrospectively by comparison with historic guideline updates and also prospectively through manual evaluation by guideline experts. The system improves precision over state-of-the-art literature research strategies while maintaining near-total recall. Detailed error analysis highlights challenges for fine-grained clinical information extraction, in particular when extracting population definitions for tumor-agnostic therapies.

Indexed as

Natural Language ProcessingSoftwareHumansResearch DesignRetrospective Studies

Identifiers

PMID35308948
PMCPMC8861732

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.